Showing 4161-4170 of 4948 results for "".
- FDA Clears Xstrahl Photoelectric Therapy Systemhttps://practicaldermatology.com/news/fda-clears-xstrahl-photoelectric-therapy-system/2458005/Xstrahl has received FDA 510K clearance for the marketing of its latest skin cancer therapy device. The Photoelectric Therapy System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachyt
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- James P. Hartman Named New Vice President and General Manager at Solta Medicalhttps://practicaldermatology.com/news/james-p-hartman-named-new-vice-president-and-general-manager-at-solta-medical/2458011/James P. Hartman is the new Vice President and general manager at Solta Medical, a division of Valeant Pharmaceuticals North America LLC. Mr. Hartman joined Solta Medical from Merz Aesthetics (a division of Merz Pharm
- Silk'n Introduces Titan by Silk'n for Home Usehttps://practicaldermatology.com/news/silkn-introduces-titan-by-silkn-for-home-use/2458025/Home-use devices represent a hot growth category, and Silk'n is now introducing Titan by Silk'n for at-home skin tightening and lifting. Titan combines infrared energy to increase blood circulation and improve skin tone and texture, LED ligh
- ISHRS: Hair Restoration Surgery at All-Time Highhttps://practicaldermatology.com/news/ishrs-hair-restoration-surgery-at-all-time-high/2458029/Hair restoration is having a moment. The worldwide volume of surgical hair restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures performed worldwide in 2016, according to the latest’s statistics from the
- Study IDs Racial and Ethnic Disparities in Pediatric Eczema Treatmenthttps://practicaldermatology.com/news/study-ids-racial-and-ethnic-disparities-in-pediatric-eczema-treatment/2458033/White children in the US are more likely to see a doctor for treatment of eczema than black children, despite the fact that the disease is likely more severe among minorities. Research from the Perelman School of Medicine at the University of Pennsylvan
- Castle Creek Pharmaceuticals Unveils First-Ever IGA Scale for EBS Clinical Researchhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-unveils-first-ever-iga-scale-for-ebs-clinical-research/2458035/Castle Creek Pharmaceuticals (CCP) has developed and validated the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical tria
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://practicaldermatology.com/news/fda-clears-fontinas-starwalker-maqx-ultra-performance-q-switched-system/2458038/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis/2458046/New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 mo